ArticleESC heart failure2026
Short-term outcomes of pediatric HeartMate 3 left ventricular assist device: single center experience.
Article in ESC heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHeart failure in paediatric patients is a complex and challenging condition. While heart transplantation is the gold standard for treating end-stage heart failure, limited donor availability necessitates alternative therapies, such as ventricular assist devices (VADs). The HeartMate 3 (HM3) VAD use in adults is well-established, but there is less data regarding outcomes in children. This study aims to evaluate the short-term outcomes of the first paediatric HM3 VAD programme in Saudi Arabia.
methodsWe conducted a retrospective cohort study involving 15 consecutive paediatric patients treated with HM3 at a single tertiary cardiac centre from 2022 to 2024. Postoperative outcomes included stroke, device thrombosis, driveline infection, hospital mortality, follow-up survival and time to transplantation.
resultsThe cohort had a mean age of 11.07 years, with a predominance of females (67%). Average body surface area was 1.2 m2 (range 0.85-1.76 m2). The most frequent diagnosis was dilated cardiomyopathy (n = 13, 87%). The median lengths of ICU and hospital stays were 42 days and 56 days, respectively. The complications included strokes (n = 2, 13%), re-exploration for bleeding (n = 1, 7%), driveline infection (n = 2, 14%) and device thrombosis (n = 1, 7%). In-hospital mortality occurred in two patients. The median follow-up period was 17 months, and 60% (n = 9) of patients underwent successful transplantation. No mortality was reported beyond hospital discharge, and the overall 1-year survival was 87%. The 1-year transplantation-free survival rate was 55%.
conclusionHM3 LVADs have favourable safety profiles and survival outcomes in paediatric patients with end-stage heart failure. These findings support HM3's as a viable option for managing advanced heart failure in the Saudi paediatric population, with further studies warranted to assess long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.